Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Makers In India Move To Lifestyle Drugs For Income

This article was originally published in PharmAsia News

Executive Summary

Indian drug makers are reshaping portfolios in an effort to gain a greater share of lifestyle medicine sales. Among them is Alembic, whose emphasis has been on antibiotic and other acute-therapy drugs, but now moving into an emphasis on cancer, cardiovascular and diabetes drugs. Alembic acquired a non-oncology portfolio from Dabur Pharma last year to give it an entry into that market. Indian drug makers see lifestyle drugs as growing from the current 14 percent to 17 percent of the market by 2010. (Click here for more
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC068922

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel